---
layout: default
title: Deferoxamina
parent: 僅模型預測 (L5)
nav_order: 68
evidence_level: L5
indication_count: 0
---

# Deferoxamina
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Deferoxamina: Evaluation Pending — Evidence Pack Incomplete

## One-Sentence Summary

Deferoxamina (deferoxamine) is a well-established iron-chelating agent used clinically for iron overload conditions.
However, the submitted Evidence Pack contains **no TxGNN-predicted indications** and no approved authorizations in the Italian market were identified,
making a standard repurposing evaluation impossible at this stage — a **Hold** decision is required until data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no authorizations found in AIFA registry |
| Predicted New Indication | Not available — no TxGNN predictions returned |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A |
| Italy Market Status | Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why This Report Cannot Be Completed

The Evidence Pack for Deferoxamina is missing two critical inputs required to generate a repurposing evaluation:

**No predicted indications were returned.** The `predicted_indications` field is empty, meaning the TxGNN model either did not process this drug or did not return a ranked output. Without a predicted target indication, none of the core sections — mechanism linkage, clinical trial evidence, or literature review — can be populated.

**No regulatory authorizations were found.** The AIFA query returned zero licenses, and the drug's original approved indication is therefore not recorded in the Evidence Pack. While deferoxamine is a known chelating agent used for iron and aluminum overload in clinical practice globally, this background knowledge cannot substitute for verified regulatory source data in a formal evaluation report.

**Mechanism of action data is absent.** The `original_moa` field is flagged as a data gap (severity: High). Without MOA data, the rationale connecting the original indication to any new indication cannot be constructed.

---

## Italy Market Information

No authorizations were found in the AIFA registry for DEFEROXAMINA at the time of this query (2026-03-29).

> Note: Deferoxamine-containing products may be registered under alternative spellings (e.g., "desferrioxamine", "deferoxamine") or brand names (e.g., Desferal). A secondary query using alternate identifiers is recommended before concluding the drug is absent from the Italian market.

---

## Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were retrieved for this submission.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack does not contain the minimum required inputs — a TxGNN prediction score and a target indication — to produce a repurposing evaluation. Proceeding without these would result in a report with no substantive content.

**To proceed, the following is needed:**

- **TxGNN output**: Re-run the prediction pipeline for DEFEROXAMINA and confirm that a ranked list of predicted indications is returned. If the drug node is absent from the knowledge graph, a mapping step is required first.
- **AIFA registry lookup**: Re-query using alternate drug name spellings and brand names (e.g., "desferrioxamine", "Desferal") to establish whether the drug is already marketed in Italy.
- **DrugBank MOA data**: The query log records a successful DrugBank hit (`result_count: 1`), but MOA was not extracted. This data should be parsed and populated before the next pipeline run.
- **TFDA package insert**: The query log also records a successful TFDA package insert retrieval (`result_count: 1`). Extract warnings, contraindications, and indication text from this document to populate the safety fields.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

